Cart 0
ADP-ribosylation and NAD+ Utilizing Enzymes
Click to zoom

Share this book

ADP-ribosylation and NAD+ Utilizing Enzymes : Methods and Protocols

1st ed. 2018

Book Details

Format Hardback or Cased Book
ISBN-10 1493985876
ISBN-13 9781493985876
Edition 1st ed. 2018
Publisher Humana Press Inc.
Imprint Humana Press Inc.
Country of Manufacture GB
Country of Publication GB
Publication Date Aug 11th, 2018
Print length 417 Pages
Ksh 23,400.00
Werezi Extended Catalogue 0 in stock

Delivery Location

Delivery fee: Select location

Secure
Quality
Fast

This volume focuses on mono-ADP-ribosylation and enzymes that use NAD+ including Sirtuins, PARPs, and bacterial and eukaryotic ADP-ribosyltransferases. The chapters in this book are organized into eight parts, and offer detailed descriptions of key protocols used to study topics such as in vitro techniques for ADP-ribosylation substrate identification; biochemical and biophysical assays of PAR-WWE domain interactions; monitoring expression and enzyme activity of ecto-ARTCs; HPLC-based enzymes assays for Sirtuins; and identifying target RNAs of PARPs. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls.

Cutting-edge and thorough, ADP-ribosylation and NAD+ Utilizing Enzymes: Methods and Protocols is a valuable resource for anyone interested in this developing and expanding field.



Get ADP-ribosylation and NAD+ Utilizing Enzymes by at the best price and quality guaranteed only at Werezi Africa's largest book ecommerce store. The book was published by Humana Press Inc. and it has pages.

Mind, Body, & Spirit

Shopping Cart

Africa largest book store

Sub Total:
Ebooks

Digital Library
Coming Soon

Our digital collection is currently being curated to ensure the best possible reading experience on Werezi. We'll be launching our Ebooks platform shortly.